Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

Amisulpride

Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).

DRUG

placebo

Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).

Trial Locations (3)

NW3 2PF

University College London, London

W6 8LN

Imperial College London, London

M13 9WL

University of Manchester, Manchester

All Listed Sponsors
collaborator

University of Manchester

OTHER

collaborator

University College, London

OTHER

lead

Imperial College London

OTHER

NCT01246232 - Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia | Biotech Hunter | Biotech Hunter